CN103263423A - Application of myriberine A in preparation of medicaments for treating or preventing canker sores - Google Patents
Application of myriberine A in preparation of medicaments for treating or preventing canker sores Download PDFInfo
- Publication number
- CN103263423A CN103263423A CN2013102193625A CN201310219362A CN103263423A CN 103263423 A CN103263423 A CN 103263423A CN 2013102193625 A CN2013102193625 A CN 2013102193625A CN 201310219362 A CN201310219362 A CN 201310219362A CN 103263423 A CN103263423 A CN 103263423A
- Authority
- CN
- China
- Prior art keywords
- myriberine
- preparation
- day
- canker sores
- medicaments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to an application of myriberine A in preparation of medicaments for treating or preventing canker sores. The use of the myriberine A in the preparation of the medicaments for treating the canker sores, disclosed by the invention, belongs to the first disclosure, as the framework type belongs to the brand new framework type, the strong activity in treatment of the canker sores is unexpected, the possibility of giving any notices by other compounds does not exist, and the myriberine A has prominent substantial characteristics; and simultaneously, the myriberine A obviously has a significant progress in the treatment of the canker sores.
Description
Technical field
The present invention relates to the new purposes of chemical compound Myriberine A, relate in particular to the application of Myriberine A in preparation treatment or prevention stomatocace medicine.
Background technology
Recurrent oral ulceration is modal disease in the diseases of oral mucosa.The first place of prevalence office diseases of oral mucosa.Sircus(1975) investigation 1587 people, prevalence is 20%.This shows that oral ulcer patient is a very huge colony.The cause of disease complexity of recurrent oral ulceration, still indeterminate so far, may be relevant with factors such as the endocrine regulation of viral infection, bacterial infection and body, immune dysfunctions.
The main treatment measure of oral ulcer comprises topical therapeutic and whole body therapeutic, because the topical therapeutic toxic and side effects is lower, the people who has therefore obtained people can.Though the buccal tablets that use the part that occurs in recent years carries, easy to use, mouthfeel and compliance are better, and as lysozyme buccal tablet, watermelon crystal buccal tablet, cydiodine etc., these medicines emphasize particularly on different fields at aspects such as sterilization, antiinflammatory, pain relievings.
The chemical compound Myriberine A that the present invention relates to is one and delivered (Sheng-Dian Huang in 2013, et al., 2012.Myriberine A, a New Alkaloid with an Unprecedented Heteropentacyclic Skeleton fromMyrioneuron faberi.Organic Letters3 (15), 590 – 593.) noval chemical compound, this chemical compound has brand-new framework types, present purposes only relates to and suppresses hepatitis C virus (Sheng-Dian Huang, et al., 2012.Myriberine A, a New Alkaloid with an Unprecedented Heteropentacyclic Skeleton fromMyrioneuron faberi.Organic Letters3 (15), 590 – 593.), belong to open first for the purposes of the MyriberineA that the present invention relates in preparation treatment or prevention stomatocace medicine, owing to belong to brand-new structure type, and it is active unexpectedly strong for treatment or prevention oral ulcer, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, be used for the treatment of simultaneously or prevent oral ulcer obviously to have obvious improvement.
Summary of the invention
The objective of the invention is to provides the application of Myriberine A in preparation treatment or prevention stomatocace medicine according to not finding in the existing Myriberine A research that it has the present situation of the report for the treatment of or prevention oral ulcer.
Described chemical compound Myriberine A structure is shown in formula I:
The purposes of the Myriberine A that the present invention relates in preparation treatment or prevention stomatocace medicine belongs to open first, because framework types belongs to brand-new framework types, and its treatment or prevention oral ulcer are active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, be used for the treatment of simultaneously or prevent oral ulcer obviously to have obvious improvement.
The specific embodiment
The preparation method of chemical compound Myriberine A involved in the present invention is referring to document (Sheng-Dian Huang, etal., 2012.Myriberine A, a New Alkaloid with an Unprecedented HeteropentacyclicSkeleton from Myrioneuron faberi.Organic Letters3 (15), 590 – 593.)
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of chemical compound Myriberine A tablet involved in the present invention:
Get 20 and digest conventional adjuvant 180 grams that compound Myriberine A adds the preparation tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of chemical compound Myriberine A capsule involved in the present invention:
Get 20 and digest conventional adjuvant such as starch 180 grams that compound Myriberine A adds the preparation capsule, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Test the anti-oral ulcer experimental study of routine 1:Myriberine A
1, test objective: whether make the oral ulcer model with phenol, give the MyriberineA of the certain number of times of oral ulcer rat model every day, observing Myriberine A has the effect that reduces ulcer.
2, be subjected to reagent thing and reagent
Cydiodine (Beijing Sihuan Medicine Science and Technology Co., Ltd); Phenol
Animal: the Wistar rat, male, body weight 240～280g
3, test method
Get 50 of rats, male, body weight 240～280g, 10% chloral hydrate anesthesia, dosage: 0.35ml/100g, (internal diameter: 3mm) lower end is flat on the cheek film at the about 1mm of rats with left bicker place with the plastic dropper of 90% phenol cotton balls after the anesthesia, calcination 30min namely sees the white infringement of the about 3mm in this place.Grouping immediately, divides 5 groups, i.e. model group (adjuvant 4 times/day does not contain medicine) by 10 every group after 24 hours; Myriberine A high dose group (4 times/day, 0.5mg/ time); Dosage among the Myriberine A (4 times/day, 0.1mg/ time); Myriberine A low dose group (4 times/day, 0.02mg/ time); Positive controls: cydiodine group (4 times/day, 0.5mg/ time).Myriberine A and cydiodine buccal tablet be pulverize before use, and administration is degree of being with the flap coverage.Observe ulcer area size (in the diameter of ulcer) and ulcer healing situation (do not have macroscopic ulcer and be considered as healing) next day after reaching each administration before the successive administration 5 days, administration, and first administration to last administration is recorded as 1,2,3,4,5,6 day respectively.Ulcer area size is checked with t, and ulcer healing rate is checked with X2.4, result of the test
The ulcer area is (table 1) relatively: Myriberine A high dose group and model group relatively played off-test on the 3rd day from administration, and significant difference is relatively arranged corresponding every day; Cydiodine group and model group relatively played off-test on the 3rd day from administration, and significant difference is relatively arranged corresponding every day; Dosage group and model group relatively played off-test on the 3rd day from administration among the Myriberine A, and significant difference is relatively arranged corresponding every day; Myriberine A low dose group and model group relatively played off-test on the 5th day from administration, and significant difference is relatively arranged corresponding every day; Dosage group and cydiodine group relatively played off-test on the 1st day from administration among the Myriberine A, and significant difference is relatively arranged corresponding every day.
The influence of table 1 pair rat ulcer area
Annotate: compare * p＜0.05, * p＜0.01 with model group.
Healing rate (table 2): model group and Myriberine A low dose group played off-test on the 1st day from administration, and ulcer is healing not; And Myriberine A high dose group just has ulcer healing from administration the 4th day, to off-test, reaches 90%; The cydiodine group has ulcer healing from administration the 4th day, to off-test, reaches 60%; The dosage group has ulcer healing from administration the 5th day among the Myriberine A, to off-test, reaches 40%.
The influence of table 2 pair rat ulcer healing time
Annotate: compare * p＜0.05, * p＜0.01 with model group.
5, conclusion
Myriberine A has the effect of obvious promotion oral ulcer healing.
Claims (1)
1.Myriberine the application of A in preparation treatment or prevention stomatocace medicine, described chemical compound MyriberineA structure is shown in formula I:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013102193625A CN103263423A (en) | 2013-06-03 | 2013-06-03 | Application of myriberine A in preparation of medicaments for treating or preventing canker sores |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013102193625A CN103263423A (en) | 2013-06-03 | 2013-06-03 | Application of myriberine A in preparation of medicaments for treating or preventing canker sores |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103263423A true CN103263423A (en) | 2013-08-28 |
Family
ID=49007119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013102193625A Pending CN103263423A (en) | 2013-06-03 | 2013-06-03 | Application of myriberine A in preparation of medicaments for treating or preventing canker sores |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103263423A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105147676A (en) * | 2015-08-14 | 2015-12-16 | 南京华宽信息咨询中心 | Medicine for preventing or treating dental ulcer |
-
2013
- 2013-06-03 CN CN2013102193625A patent/CN103263423A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105147676A (en) * | 2015-08-14 | 2015-12-16 | 南京华宽信息咨询中心 | Medicine for preventing or treating dental ulcer |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103263423A (en) | Application of myriberine A in preparation of medicaments for treating or preventing canker sores | |
| CN103585147B (en) | Application of Nitrosporeusines A in preparation of oral ulcer treatment or prevention medicines | |
| CN103462951B (en) | Application of scopariusins in preparation of medicine treating or preventing canker sore | |
| CN102872060B (en) | Application of Gypensapogenin B to preparing drugs for treating or preventing canker sores | |
| CN102988382B (en) | Application of Houttuynoid C for preparing medicine for treating or preventing dental ulcer | |
| CN103356653B (en) | The application of Chukrasone A in preparation treatment or preventing canker sore medicine | |
| CN107501435A (en) | The extracting method of pachymaran and its application | |
| CN103599104B (en) | Application of Caesanines D in drug for treating or preventing dental ulcer | |
| CN103479624B (en) | Application of Racemosins A in preparation of oral ulcer treatment or prevention medicines | |
| CN106344555A (en) | Application of Fistulains B in drugs for dental ulcer prevention or treatment | |
| CN102872056B (en) | Application of Gypensapogenin A to preparing drugs for treating or preventing canker sores | |
| CN103393655A (en) | Application of Sarcaboside B to medicament for treatment and prevention of oral ulcer | |
| CN103505464B (en) | The application of Phyllanthoid A in preparation treatment or preventing canker sore medicine | |
| CN103356549A (en) | Application of Sarcaboside A in medicine for treating or preventing oral ulcer | |
| CN103381160A (en) | Applications of Chukrasone B in medicines used for curing or preventing oral ulcer | |
| CN103027918A (en) | Application of Houttuynoid E in preparation of drug for treating or preventing oral ulcer | |
| CN106266308A (en) | A kind of pharmaceutical composition treating pneumonia and preparation method thereof | |
| CN103127077A (en) | Application of Aphanamixoid A to dental ulcer treatment or prevention medicine | |
| CN103462998A (en) | Application of Neonectrolide A in preparing medicament for treating or preventing dental ulcer | |
| CN103638005B (en) | The application of Hippolachnin A in treatment or preventing canker sore medicine | |
| CN103315994A (en) | Application of Aphanamgrandiol A in preparation of medicine used for preventing or treating oral ulcer | |
| CN109692255A (en) | A kind of Chinese medicine composition and its preparation method and application for treating acute tracheobronchitis | |
| CN105232531A (en) | Application of Penifulvin A in preparing drugs for treating or preventing dental ulcers | |
| CN103127086A (en) | Application of Eryngiolide A in medicines curing or preventing dental ulcer | |
| CN105434428A (en) | Applications of Volvalerelactones B in preparing drugs used for treating or preventing dental ulcer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130828 |